FilingSEC EDGAR6-K
Radiopharm Theranostics dosed first patient in second cohort of RV-01 Phase 1/2a trial.
· SEC accepted
StagePhase 1/2a
Filing content
The company dosed the first patient in the second cohort of its Phase 1/2a clinical trial of RV-01 at a 70 mCi dose level for B7-H3 expressing solid tumors.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…